JP2017504632A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504632A5 JP2017504632A5 JP2016549045A JP2016549045A JP2017504632A5 JP 2017504632 A5 JP2017504632 A5 JP 2017504632A5 JP 2016549045 A JP2016549045 A JP 2016549045A JP 2016549045 A JP2016549045 A JP 2016549045A JP 2017504632 A5 JP2017504632 A5 JP 2017504632A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- effective amount
- crystalline form
- liver fibrosis
- jnk1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 108700027648 Mitogen-Activated Protein Kinase 8 Proteins 0.000 claims 18
- 108700027653 Mitogen-Activated Protein Kinase 9 Proteins 0.000 claims 18
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 claims 18
- 208000019425 cirrhosis of liver Diseases 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 9
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 9
- 102000001253 Protein Kinase Human genes 0.000 claims 9
- 206010039710 Scleroderma Diseases 0.000 claims 9
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 9
- 206010042953 Systemic sclerosis Diseases 0.000 claims 9
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 9
- 229940125904 compound 1 Drugs 0.000 claims 9
- 206010012601 diabetes mellitus Diseases 0.000 claims 9
- 230000002401 inhibitory effect Effects 0.000 claims 9
- 206010025135 lupus erythematosus Diseases 0.000 claims 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims 9
- 230000001684 chronic effect Effects 0.000 claims 8
- 208000017169 kidney disease Diseases 0.000 claims 8
- 206010063209 Chronic allograft nephropathy Diseases 0.000 claims 1
- 201000001200 Crouzon syndrome-acanthosis nigricans syndrome Diseases 0.000 claims 1
- QBBRJRLJWXRSHQ-CKYFFXLPSA-N C[C@H](CC[C@H](C1)Nc2nc(NC(C)(C)C)ncc2C(N)=O)[C@@H]1O Chemical compound C[C@H](CC[C@H](C1)Nc2nc(NC(C)(C)C)ncc2C(N)=O)[C@@H]1O QBBRJRLJWXRSHQ-CKYFFXLPSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461933636P | 2014-01-30 | 2014-01-30 | |
| US61/933,636 | 2014-01-30 | ||
| US201462025161P | 2014-07-16 | 2014-07-16 | |
| US62/025,161 | 2014-07-16 | ||
| PCT/US2015/013412 WO2015116755A2 (en) | 2014-01-30 | 2015-01-29 | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019071044A Division JP6742466B2 (ja) | 2014-01-30 | 2019-04-03 | ２−（ｔｅｒｔ−ブチルアミノ）−４−（（１Ｒ，３Ｒ，４Ｒ）−３−ヒドロキシ−４−メチルシクロヘキシルアミノ）−ピリミジン−５−カルボキサミドの固体形態、その組成物、及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017504632A JP2017504632A (ja) | 2017-02-09 |
| JP2017504632A5 true JP2017504632A5 (enExample) | 2018-04-19 |
Family
ID=53678405
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549045A Pending JP2017504632A (ja) | 2014-01-30 | 2015-01-29 | ２−（ｔｅｒｔ−ブチルアミノ）−４−（（１Ｒ，３Ｒ，４Ｒ）−３−ヒドロキシ−４−メチルシクロヘキシルアミノ）−ピリミジン−５−カルボキサミドの固体形態、その組成物、及びその使用方法 |
| JP2019071044A Active JP6742466B2 (ja) | 2014-01-30 | 2019-04-03 | ２−（ｔｅｒｔ−ブチルアミノ）−４−（（１Ｒ，３Ｒ，４Ｒ）−３−ヒドロキシ−４−メチルシクロヘキシルアミノ）−ピリミジン−５−カルボキサミドの固体形態、その組成物、及びその使用方法 |
| JP2020127493A Active JP7317768B2 (ja) | 2014-01-30 | 2020-07-28 | ２－（ｔｅｒｔ－ブチルアミノ）－４－（（１Ｒ，３Ｒ，４Ｒ）－３－ヒドロキシ－４－メチルシクロヘキシルアミノ）－ピリミジン－５－カルボキサミドの固体形態、その組成物、及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019071044A Active JP6742466B2 (ja) | 2014-01-30 | 2019-04-03 | ２−（ｔｅｒｔ−ブチルアミノ）−４−（（１Ｒ，３Ｒ，４Ｒ）−３−ヒドロキシ−４−メチルシクロヘキシルアミノ）−ピリミジン−５−カルボキサミドの固体形態、その組成物、及びその使用方法 |
| JP2020127493A Active JP7317768B2 (ja) | 2014-01-30 | 2020-07-28 | ２－（ｔｅｒｔ－ブチルアミノ）－４－（（１Ｒ，３Ｒ，４Ｒ）－３－ヒドロキシ－４－メチルシクロヘキシルアミノ）－ピリミジン－５－カルボキサミドの固体形態、その組成物、及びその使用方法 |
Country Status (32)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20240097T1 (hr) | 2011-04-22 | 2024-03-29 | Signal Pharmaceuticals, Llc | Supstituirani diaminokarboksamid i diaminokarbonitril pirimidini, njihovi pripravci i postupci liječenja s njima |
| NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
| WO2016100310A1 (en) | 2014-12-16 | 2016-06-23 | Signal Pharmaceuticals, Llc | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide |
| EP3233808B1 (en) | 2014-12-16 | 2021-07-14 | Signal Pharmaceuticals, LLC | Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin |
| CA2975260C (en) | 2015-01-29 | 2024-05-21 | Signal Pharmaceuticals Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| ES2994877T3 (en) | 2015-07-24 | 2025-02-03 | Celgene Corp | Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
| CN111934089B (zh) | 2019-05-13 | 2021-10-26 | 华为技术有限公司 | 天线装置及移动终端 |
| CN113698408B (zh) * | 2020-05-22 | 2025-07-25 | 武汉朗来科技发展有限公司 | Jnk抑制剂、其药物组合物和用途 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH549339A (de) | 1971-05-12 | 1974-05-31 | Ciba Geigy Ag | Herbizides mittel. |
| US5852028A (en) * | 1995-12-18 | 1998-12-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| US5811428A (en) * | 1995-12-18 | 1998-09-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
| US5935966A (en) * | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| AU1507199A (en) | 1997-12-15 | 1999-07-05 | Yamanouchi Pharmaceutical Co., Ltd. | Novel pyrimidine-5-carboxamide derivatives |
| DE69933680T2 (de) | 1998-08-29 | 2007-08-23 | Astrazeneca Ab | Pyrimidine verbindungen |
| AU5107900A (en) | 1999-06-09 | 2000-12-28 | Yamanouchi Pharmaceutical Co., Ltd. | Novel heterocyclic carboxamide derivatives |
| AU5108000A (en) | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
| US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| AU2003220968A1 (en) | 2002-03-28 | 2003-10-13 | Kyowa Hakko Kogyo Co., Ltd. | Anti-inflammatory agent |
| EP1518855B1 (en) * | 2002-06-28 | 2011-10-26 | Astellas Pharma Inc. | Diaminopyrimidinecarboxa mide derivative |
| BR0313059B8 (pt) | 2002-07-29 | 2021-07-27 | Rigel Pharmaceuticals | composto, e, composição farmacêutica |
| WO2004053071A2 (en) * | 2002-12-09 | 2004-06-24 | Judith Kelleher-Andersson | Method for discovering neurogenic agents |
| WO2004054617A1 (ja) | 2002-12-13 | 2004-07-01 | Kyowa Hakko Kogyo Co., Ltd. | 中枢疾患の予防および／または治療剤 |
| DE602004022633D1 (de) | 2003-01-30 | 2009-10-01 | Boehringer Ingelheim Pharma | 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen |
| TWI378923B (en) | 2003-08-15 | 2012-12-11 | Novartis Ag | Pyrimidine derivatives |
| CN1871009A (zh) | 2003-09-24 | 2006-11-29 | 惠氏控股公司 | 作为抗癌剂的5－芳基嘧啶 |
| WO2005095382A1 (ja) | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | 抗腫瘍剤 |
| WO2006014482A1 (en) | 2004-07-08 | 2006-02-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of pkc-theta |
| JP2008512429A (ja) | 2004-09-10 | 2008-04-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロフルミラストとｓｙｋインヒビターとの組合せ物並びにその使用方法 |
| EP1796679A1 (en) | 2004-09-10 | 2007-06-20 | Altana Pharma AG | Ciclesonide and syk inhibitor combination and methods of use thereof |
| JP2006124387A (ja) | 2004-09-30 | 2006-05-18 | Taisho Pharmaceut Co Ltd | 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法 |
| RU2410379C2 (ru) | 2004-09-30 | 2011-01-27 | Тиботек Фармасьютикалз Лтд. | 5-замещенные пиримидины, ингибирующие вич |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| WO2006099231A1 (en) | 2005-03-10 | 2006-09-21 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives for treatment of hyperproliferative disorders |
| DE102005062742A1 (de) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
| CA2657260A1 (en) | 2006-07-21 | 2008-01-24 | Novartis Ag | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
| US20080139531A1 (en) | 2006-12-04 | 2008-06-12 | Alcon Manufacturing Ltd. | Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair |
| AP2009005010A0 (en) | 2007-04-18 | 2009-10-31 | Pfizer Prod Inc | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
| US20090036440A1 (en) | 2007-04-27 | 2009-02-05 | Astrazeneca Ab | Novel pyrimidine derivatives - 816 |
| WO2009010789A2 (en) | 2007-07-16 | 2009-01-22 | Astrazeneca Ab | Pyrimidine derivatives 934 |
| CN101903357A (zh) | 2007-07-17 | 2010-12-01 | 里格尔药品股份有限公司 | 作为pkc抑制剂的环状胺取代的嘧啶二胺 |
| JP5705720B2 (ja) * | 2008-04-16 | 2015-04-22 | ポートラ ファーマシューティカルズ， インコーポレイテッド | Ｓｙｋまたはｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド |
| KR20100132550A (ko) | 2008-04-16 | 2010-12-17 | 포톨라 파마슈티컬스, 인코포레이티드 | ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드 |
| JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| EP2300013B2 (en) | 2008-05-21 | 2024-11-13 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
| UY31929A (es) | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
| NZ603525A (en) | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| WO2010024430A1 (ja) | 2008-09-01 | 2010-03-04 | アステラス製薬株式会社 | 2,4-ジアミノピリミジン化合物 |
| CA2737738A1 (en) | 2008-09-18 | 2010-03-25 | Astellas Pharma Inc. | Heterocyclic carboxamide compounds |
| TW201016676A (en) | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| CN102272291B (zh) | 2008-10-31 | 2018-01-16 | 詹森生物科技公司 | 人胚胎干细胞向胰腺内分泌谱系的分化 |
| EP2375899B1 (en) | 2009-01-12 | 2015-02-25 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof in the treatment of diabetes |
| MX2011007499A (es) * | 2009-01-13 | 2011-08-04 | Glaxo Group Ltd | Derivados de pirimidin-carboxamida como inhibidores de la cinasa syk. |
| ES2635504T3 (es) | 2009-01-21 | 2017-10-04 | Rigel Pharmaceuticals, Inc. | Derivados de N2-(3-piridilo o fenil)-N4-(4-piperidil)-2,4-pirimidinadiamina útiles en el tratamiento de enfermedades inflamatorias, toimmunitarias o proliferativas |
| US8367689B2 (en) * | 2009-05-06 | 2013-02-05 | Portola Pharmaceuticals, Inc. | Inhibitors of JAK |
| JP5364159B2 (ja) * | 2009-05-08 | 2013-12-11 | アステラス製薬株式会社 | ジアミノへテロ環カルボキサミド化合物 |
| CN102498110A (zh) | 2009-06-10 | 2012-06-13 | 雅培制药有限公司 | 作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶 |
| JP2012197231A (ja) | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| WO2011065800A2 (ko) | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
| US20110130415A1 (en) * | 2009-12-01 | 2011-06-02 | Rajinder Singh | Protein kinase c inhibitors and uses thereof |
| JP6035238B2 (ja) | 2010-07-21 | 2016-11-30 | ライジェル ファーマシューティカルズ， インコーポレイテッド | プロテインキナーゼｃ阻害剤およびその使用 |
| US8580805B2 (en) * | 2010-08-31 | 2013-11-12 | Hubert Maehr | Pyrimidine carboxamide derivatives |
| WO2012044936A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide |
| WO2012045010A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combinations of 4-(3-(2h-1,2,3-triazo-2-yl) phenylamino)-2-((1r,2s)-2-aminocyclohexylamino) pyrimidine-5-carboxamide and fludarabine |
| HRP20240097T1 (hr) * | 2011-04-22 | 2024-03-29 | Signal Pharmaceuticals, Llc | Supstituirani diaminokarboksamid i diaminokarbonitril pirimidini, njihovi pripravci i postupci liječenja s njima |
| WO2013152198A1 (en) * | 2012-04-04 | 2013-10-10 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| CA2892677A1 (en) * | 2012-12-04 | 2014-06-12 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| CA2904610A1 (en) * | 2013-03-14 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
| CN104262328B (zh) * | 2013-09-18 | 2016-09-07 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
| AR099376A1 (es) * | 2013-12-20 | 2016-07-20 | Signal Pharm Llc | Compuestos de diaminopirimidilo sustituidos, sus composiciones y métodos de tratamiento con aquellos |
| NZ715903A (en) * | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
| WO2016100310A1 (en) * | 2014-12-16 | 2016-06-23 | Signal Pharmaceuticals, Llc | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide |
| CA2975260C (en) * | 2015-01-29 | 2024-05-21 | Signal Pharmaceuticals Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
-
2014
- 2014-09-03 NZ NZ715903A patent/NZ715903A/en unknown
-
2015
- 2015-01-29 EA EA201691544A patent/EA031671B1/ru not_active IP Right Cessation
- 2015-01-29 MX MX2020003173A patent/MX391127B/es unknown
- 2015-01-29 MY MYPI2016702761A patent/MY180020A/en unknown
- 2015-01-29 US US14/608,314 patent/US9365524B2/en active Active
- 2015-01-29 NZ NZ722412A patent/NZ722412A/en unknown
- 2015-01-29 SM SM20200430T patent/SMT202000430T1/it unknown
- 2015-01-29 HU HUE15743503A patent/HUE051266T2/hu unknown
- 2015-01-29 TW TW104103137A patent/TWI631108B/zh active
- 2015-01-29 NZ NZ761068A patent/NZ761068A/en unknown
- 2015-01-29 SG SG11201606054SA patent/SG11201606054SA/en unknown
- 2015-01-29 CA CA2938187A patent/CA2938187C/en active Active
- 2015-01-29 CN CN202110386098.9A patent/CN113717110A/zh active Pending
- 2015-01-29 HR HRP20201244TT patent/HRP20201244T1/hr unknown
- 2015-01-29 DK DK15743503.3T patent/DK3099302T3/da active
- 2015-01-29 PT PT157435033T patent/PT3099302T/pt unknown
- 2015-01-29 AU AU2015211036A patent/AU2015211036B2/en active Active
- 2015-01-29 CR CR20160346A patent/CR20160346A/es unknown
- 2015-01-29 MX MX2016009989A patent/MX373804B/es active IP Right Grant
- 2015-01-29 EP EP20178344.6A patent/EP3738954A1/en active Pending
- 2015-01-29 KR KR1020227013115A patent/KR102760889B1/ko active Active
- 2015-01-29 SI SI201531322T patent/SI3099302T1/sl unknown
- 2015-01-29 JP JP2016549045A patent/JP2017504632A/ja active Pending
- 2015-01-29 CN CN202110386057.XA patent/CN113717109A/zh active Pending
- 2015-01-29 BR BR112016017776A patent/BR112016017776A8/pt not_active Application Discontinuation
- 2015-01-29 CN CN201580016658.4A patent/CN106163523A/zh active Pending
- 2015-01-29 RS RS20200970A patent/RS60715B1/sr unknown
- 2015-01-29 ES ES15743503T patent/ES2811834T3/es active Active
- 2015-01-29 BR BR122020003206-5A patent/BR122020003206B1/pt active IP Right Grant
- 2015-01-29 KR KR1020167023497A patent/KR102505677B1/ko active Active
- 2015-01-29 EP EP15743503.3A patent/EP3099302B1/en active Active
- 2015-01-29 LT LTEP15743503.3T patent/LT3099302T/lt unknown
- 2015-01-29 PL PL15743503T patent/PL3099302T3/pl unknown
- 2015-01-29 PE PE2016001300A patent/PE20161437A1/es not_active Application Discontinuation
- 2015-01-29 WO PCT/US2015/013412 patent/WO2015116755A2/en not_active Ceased
- 2015-01-29 EA EA201792281A patent/EA036964B1/ru not_active IP Right Cessation
-
2016
- 2016-05-12 US US15/152,653 patent/US9814713B2/en active Active
- 2016-07-25 IL IL246931A patent/IL246931B/en active IP Right Grant
- 2016-07-26 PH PH12016501472A patent/PH12016501472B1/en unknown
- 2016-07-28 SA SA516371578A patent/SA516371578B1/ar unknown
- 2016-07-29 MX MX2019005715A patent/MX2019005715A/es unknown
- 2016-07-29 CL CL2016001927A patent/CL2016001927A1/es unknown
-
2017
- 2017-10-09 US US15/727,659 patent/US10226461B2/en active Active
-
2019
- 2019-02-04 US US16/266,793 patent/US10517873B2/en active Active
- 2019-04-03 JP JP2019071044A patent/JP6742466B2/ja active Active
- 2019-11-11 US US16/679,592 patent/US11241430B2/en active Active
-
2020
- 2020-03-26 AU AU2020202146A patent/AU2020202146B2/en active Active
- 2020-06-11 IL IL275305A patent/IL275305B/en unknown
- 2020-07-28 JP JP2020127493A patent/JP7317768B2/ja active Active
- 2020-08-12 CY CY20201100757T patent/CY1123267T1/el unknown
-
2021
- 2021-12-27 US US17/562,933 patent/US20220378785A1/en not_active Abandoned
-
2024
- 2024-06-26 US US18/754,494 patent/US20250000860A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201244T1 (hr) | Kristalni oblici 2-(tert-butilamino)-4-((1r,3r,4r)-3-hidroksi-4-metilcikloheksilamino)-pirimidin-5-karboksamida | |
| JP2018024682A5 (enExample) | ||
| NZ746950A (en) | Heterocyclic gpr119 agonist compounds | |
| JP2017509667A5 (enExample) | ||
| MX2012007925A (es) | Formas polimorficas, cristalinas y de mesofase de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-ilti o)acetato de sodio, y usos de las mismas. | |
| JP2013525444A5 (enExample) | ||
| JP2015127293A5 (enExample) | ||
| DK2878598T3 (da) | Krystallinsk form af 4-[5-(pyridin-4-yl)-1h-1,2,4-triazol-3-yl]pyridin-2-carbonitril | |
| JP2016072210A5 (enExample) | ||
| GEP20186841B (en) | Stabilized crystal of tipiracil hydrochloride, and crystallization method for same | |
| Limoges et al. | Long-term hydrological changes in the northeastern Gulf of Mexico (ODP-625B) during the Holocene and late Pleistocene inferred from organic-walled dinoflagellate cysts | |
| LT4331607T (lt) | Kieta farmacinė kompozicija, kurios sudėtyje yra 2-{4-[n-(5,6- difenilpirazin-2-il)-n-izopropilamino]butiloksi}-n-(metilsulfonil) acetamidas | |
| BR112015023218A2 (pt) | formas sólidas de 5- (halometil)furfural e métodos para preparar as mesmas | |
| Tahmasebifar et al. | Structural and mechanical characteristics of hydroxyapatite and tri-calcium phosphates doped with Al3+ and F-ions | |
| WO2016068453A8 (en) | Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component | |
| SI3298008T1 (sl) | Kristalinična oblika spojine (S)-3-(4-(5-(2-ciklopentil-6-metoksi-piridin-4-IL)-(1,2,4)oksadiazol-3- IL)-2-etil-6-metil-fenoksi)-propan 1,2-diol | |
| WO2016016774A8 (en) | Crystalline forms of canagliflozin | |
| WO2013088384A3 (en) | Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof | |
| GB201901761D0 (en) | Phase change materials (PCMs) with solid to solid transitions | |
| PL3019182T3 (pl) | Kompozycja zawierająca oczyszczony wyciąg wyodrębniony z pseudolysimachion rotundum var. subintegrum zawierający dużą ilość składnika czynnego lub związki z niego wyodrębnione jako składnik czynny do zapobiegania lub leczenia przewlekłej obturacyjnej choroby płuc oraz jej zastosowania | |
| Bennett et al. | Correction to: Mixture deconvolution by massively parallel sequencing of microhaplotypes | |
| AR119477A2 (es) | Formas sólidas amorfas de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida y dichas formas cristalinas para uso en el tratamiento de una enfermedad | |
| 허만규 et al. | Synthesis of down-converting red emission Ca14Zn6Al10-xMnxO35 phosphors for use in solar cells | |
| JP2016155986A5 (enExample) | ||
| PL3172191T3 (pl) | Nowy związek wyizolowany z Pseudolysimachion rotundum var. subintegrum zawierający obfitą ilość aktywnego składnika, kompozycja go zawierająca do zapobiegania lub leczenia choroby alergicznej, choroby zapalnej, astmy lub chronicznej obturacyjnej choroby płuc i jej zastosowanie |